Get the Stockscreener App
1.22
2.39%
-0.0299
After Hours:
1.22
Clearmind Medicine Inc stock is traded at $1.22, with a volume of 22,300.
It is down -2.39% in the last 24 hours and down -6.87% over the past month.
Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
See More
Previous Close:
$1.2499
Open:
$1.23
24h Volume:
22,300
Relative Volume:
0.01
Market Cap:
$5.03M
Revenue:
-
Net Income/Loss:
$-6.78M
P/E Ratio:
-0.3415
EPS:
-3.5729
Net Cash Flow:
$-4.67M
1W Performance:
+0.83%
1M Performance:
-6.87%
6M Performance:
+6.09%
1Y Performance:
+662.50%
1-Day Range:
$1.22
$1.25
1-Week Range:
$1.205
$1.26
52-Week Range:
$0.10
$6.80
Clearmind Medicine Inc Stock (CMND) Company Profile
Clearmind Medicine Inc Stock (CMND) Latest News
Clearmind Medicine appoints new board member - Investing.com
Clearmind, SciSparc slide amid weight-loss study results - MSN
Could Psychedelics End Binge Drinking? A Breakthrough Patent Says Yes - MSN
Clearmind Medicine patents new addiction treatment - Investing.com India
Clearmind Medicine patents new addiction treatment - Investing.com
SciSparc Unveils Breakthrough Ibogaine Therapy Patent - TipRanks
Clearmind Medicine Announces the Notice of an International Patent Application for Pioneering - The Bakersfield Californian
SciSparc-Clearmind Medicine Collaboration Announces the - GlobeNewswire
SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy - StockTitan
Contrasting Clearmind Medicine (NASDAQ:CMND) and Phio Pharmaceuticals (NASDAQ:PHIO) - Defense World
Clearmind Medicine files patent for PTSD treatment compounds - Investing.com
Clearmind Medicine files patent for PTSD treatment compounds - Investing.com India
SciSparc shares up on patents filed for psychedelic compounds with Clearmind - MSN
SciSparc and Clearmind Innovate Mental Health Treatment - TipRanks
Clearmind Medicine files patent for novel MDMA therapy - Investing.com
SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment - Yahoo Finance UK
SciSparc-Clearmind Medicine Collaboration Leads to - GlobeNewswire
SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent ... - The Bakersfield Californian
SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment - StockTitan
A History of Outperforming Analyst Forecasts and Beating the Odds: Clearmind Medicine Inc (CMND) - SETE News
Financial Metrics Check: Clearmind Medicine Inc (CMND)’s Ratios for Trailing Twelve Months - The Dwinnex
Clearmind and SciSparc file patent for ketamine-based therapy - Investing.com
SciSparc and Clearmind Innovate in Mental Health Therapy - TipRanks
Clearmind Medicine Announces Publication of its Patent Application for Innovative Ketamine-Based Combination Treatment - Morningstar
Could Psychedelics End Binge Drinking? A Breakthrough Patent Says Yes - Benzinga
CMND’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
Clearmind receives patent for drug to treat binge behavior - Green Market Report
Clearmind Medicine Inc (CMND) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle
Clearmind Medicine secures new US patent for binge behavior regulator - Investing.com India
Clearmind Medicine secures new US patent for binge behavior regulator - Investing.com
Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment - Yahoo Finance
Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment - Morningstar
Clearmind Medicine Inc (CMND) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
Is CMND’s price to cash per share ratio a concern for investors? - US Post News
Financial Metrics Unveiled: Clearmind Medicine Inc (CMND)’s Key Ratios in the Spotlight - The Dwinnex
Thinking about buying stock in Brainstorm Cell Therapeutics, Cle - GuruFocus.com
Clearmind, Yissum Apply for International Patent for Psychedelics - MarketWatch
Clearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental Disorders - StockTitan
Clearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental Disorders - Morningstar
Clearmind Medicine (NASDAQ:CMND) Stock Price Down 0.8% - Defense World
Why Doximity Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket - Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday - InvestorPlace
Clearmind Medicine: New Scientific Publication Shows MEAI's Potential as a Novel Weight Loss Drug - EIN News
SciSparc and Clearmind report progress in obesity treatment - Investing.com
Move over Ozempic, psychedelics might help people lose weight - Green Market Report
SciSparc’s Collaboration with Clearmind Medicine Continues - GlobeNewswire
SciSparc’s Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug - StockTitan
Clearmind gains on exclusive global rights to psychedelic compounds for PTSD treatment - MSN
Clearmind Medicine Concludes the Successful Participation in the Psychedelic Medicine – Israel 2024 - EIN News
Clearmind Medicine Concludes the Successful Participation in the Psychedelic Medicine – Israel 2024 Conference: Presented Industry Leaders its Groundbreaking Research - Morningstar
Longeveron® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer’s Disease at the Alzheimer’s Association International Conference® (AAIC) - Yahoo Finance
Clearmind Medicine Inc Stock (CMND) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):